The UK and US have hammered out a key trade agreement that will keep zero import taxes on British drug shipments being sold in the American market.
The Terms of the Accord
As part of the deal, the UK has pledged to increase spending on pharmaceuticals through the NHS. This move ensures that tariffs on these vital products will stay at zero for a period of 36 months.
This agreement comes after previous threats to dramatically increase import taxes on branded pharmaceutical imports, with potential rates floated reaching 100%.
"This agreement with the Britain bolsters the worldwide climate for new treatments and introduces long-overdue fairness to U.S.–U.K. medicine commerce," an announcement said.
Economic Impact
Pharmaceuticals are one of the UK's biggest export categories to the US, which is clearly the primary buyer for large UK drugmakers.
Statistics indicate that in the one-year period leading up to the third quarter, the UK sold drugs worth over eleven billion pounds to the US. This value represented a significant portion of British export trade in that period.
"This guarantee safeguards jobs, stimulates capital expenditure and paves the way for the UK to become a global hub for life sciences," a minister remarked.
Detailed British Pledges
The deal includes several specific changes from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a aim to raise total health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The sum drug companies must refund to the NHS to control costs will be limited at fifteen percent. Previously, repayments exceeded twenty percent.
Industry Background
The pact takes place against a long-running dispute between the pharmaceutical industry and the UK government over medicine costs and approval rates.
The disagreement were heightened by assertions that American consumers were paying a premium for the same drugs than people in the Britain and the EU.
In recent months, several significant manufacturing plans in the UK have been halted or cancelled, while major expansions have been announced toward American operations.
One official stated that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had declined as a share of its total funding over the previous ten-year period.
